RxDoctor Payments DataLook up a doctor →

Theodore Gourdin, MD

Medical Oncology · Charleston, SCNPI 1427225069

Payments from drug & device makers

$2,600,398in general payments, 2019–2025

Across 622 payments — averaging $4180.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.4M
  • Ferring Pharmaceuticals Inc.$339K
  • Seagen Inc.$246K
  • Exelixis Inc.$205K
  • Eisai Inc.$186K
  • EMD Serono, Inc.$128K
  • plus $97K from 11 others
$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,600,398 in reported general payments places this provider in the 95th percentile of 29 medical oncology providers in South Carolina.

See all medical oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,756
Medicare patients
256
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →